• Cidara Therapeutics Inc CDTX.OQ reported a quarterly adjusted loss of $2.45​​ per share for the quarter , lower than the same quarter last year, when the company reported EPS of $-1.80. The mean expectation of three analysts for the quarter was for a loss of $4.25 per share. Wall Street expected results to range from $-5.66 to $-1.87 per share.

• Reported revenue was zero​; analysts expected $433.33 thousand.

• Cidara Therapeutics Inc's reported EPS for the quarter was a loss of $2.45​.

• The company reported a quarterly loss of $15.99 million.

• Cidara Therapeutics Inc shares had risen by 22.0% this quarter and lost 17.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 21.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Cidara Therapeutics Inc is 29.00

This summary was machine generated from LSEG data November 8 at 09:04 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)